Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Nabriva Therapeutics stock

NBRV
IE00BL53QQ85
A2QKWR

Price

0.45
Today +/-
+0
Today %
+0 %
P

Nabriva Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Nabriva Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Nabriva Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Nabriva Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Nabriva Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Nabriva Therapeutics Stock Price History

DateNabriva Therapeutics Price
9/29/20230.45 undefined
9/28/20230.42 undefined

Nabriva Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nabriva Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nabriva Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nabriva Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nabriva Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nabriva Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nabriva Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nabriva Therapeutics’s growth potential.

Nabriva Therapeutics Revenue, EBIT and net profit per share

DateNabriva Therapeutics RevenueNabriva Therapeutics EBITNabriva Therapeutics Net Income
2027e191.91 M undefined56.56 M undefined815.86 M undefined
2026e167.1 M undefined37.19 M undefined553.19 M undefined
2025e136.58 M undefined15.9 M undefined244.35 M undefined
2024e105.91 M undefined-3.65 M undefined-63.8 M undefined
2023e72.19 M undefined-31.8 M undefined-594.59 M undefined
202236.94 M undefined-51.17 M undefined-57.19 M undefined
202128.9 M undefined-48.53 M undefined-49.45 M undefined
20205.03 M undefined-66.13 M undefined-69.48 M undefined
20199.48 M undefined-79.49 M undefined-82.76 M undefined
20189.66 M undefined-114.38 M undefined-114.78 M undefined
20175.32 M undefined-73.77 M undefined-74.36 M undefined
20166.48 M undefined-55.05 M undefined-54.89 M undefined
20153.77 M undefined-27.76 M undefined-46.96 M undefined
20142.4 M undefined-10.7 M undefined-14.22 M undefined
20130 undefined21.45 M undefined14.88 M undefined

Nabriva Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20132014201520162017201820192020202120222023e2024e2025e2026e2027e
02365995283672105136167191
--50.00100.00-16.6780.00--44.44460.0028.57100.0045.8329.5222.7914.37
---366.67-500.00--100.0080.0053.5722.22-----
00-11-30009415800000
21-10-27-55-73-114-79-66-48-51-31-3153756
--500.00-900.00-916.67-1,460.00-1,266.67-877.78-1,320.00-171.43-141.67-43.06-2.8611.0322.1629.32
14-14-46-54-74-114-82-69-49-57-594-63244553815
--200.00228.5717.3937.0454.05-28.07-15.85-28.9916.33942.11-89.39-487.30126.6447.38
0.20.20.20.212.985.087.420.511.732.6800000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Nabriva Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Nabriva Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2013201420152016201720182019202020212022
                   
4.52.1111.483.986.9102.286.241.3847.6812.41
000001.5008.783.21
000003.92.703.973.53
0000000.75.8214.519.68
0.50.10.61.21.61.21.66.115.332.27
52.211285.188.5108.891.253.3180.2731.1
0.50.40.40.51.31.12.50.770.230.28
0000000000
00400400400400400370380378
00030020010010080313
0000000000
0.40.40.61.4000000
0.90.81.42.61.91.631.220.640.66
5.93113.487.790.4110.494.254.5380.9131.77
                   
0.50.42.42.90.40.70.90.210.570.03
0000000000
-23.6-36.9102.574.381.767.940.332.952.763.23
003.800000.030.030.03
0000000000
-23.1-36.5108.777.282.168.641.233.1453.353.29
0.50.32.92.65.13.34.72.894.375.43
3.43.15.311.4712.98.111.028.2913.24
1.18.20.721.21.63.92.585.914.1
0000000000
15.623.2000002.043.774.83
20.634.88.91613.317.816.718.5222.3427.6
0.73.4000.223.734.55.694.270.39
0000000000
9.12.90.10.10.20.31.71.090.950.48
9.86.30.10.10.42436.26.785.220.87
30.441.1916.113.741.852.925.327.5628.47
7.34.6117.793.395.8110.494.158.4480.9131.76
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Nabriva Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Nabriva Therapeutics's financial health and stability.

Assets

Nabriva Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Nabriva Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Nabriva Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Nabriva Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (k)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (k)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2013201420152016201720182019202020212022
14-14-46-54-74-114-82-69-49-57
0000000000
00001,00000000
1023-140-11-1413
-21222243710946
0010002100
0000000001,000
-4-11-21-49-69-72-71-71-59-36
0000-100000
30-762349-40000
30-762350-40000
0000000000
18-300259-300-2
00106080744861705
191332272925626661
003022-8-6-1-4-30
0000000000
0-234-35315-15-446-35
-5.01-11.5-22.08-49.92-70.52-72.95-71.95-71.44-59.58-36.92
0000000000

Nabriva Therapeutics stock margins

The Nabriva Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nabriva Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nabriva Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nabriva Therapeutics's sales revenue. A higher gross margin percentage indicates that the Nabriva Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nabriva Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nabriva Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nabriva Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nabriva Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nabriva Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nabriva Therapeutics Margin History

Nabriva Therapeutics Gross marginNabriva Therapeutics Profit marginNabriva Therapeutics EBIT marginNabriva Therapeutics Profit margin
2027e22.62 %29.47 %425.13 %
2026e22.62 %22.26 %331.05 %
2025e22.62 %11.64 %178.91 %
2024e22.62 %-3.45 %-60.24 %
2023e22.62 %-44.06 %-823.66 %
202222.62 %-138.55 %-154.83 %
202154.5 %-167.95 %-171.14 %
202084.76 %-1,315.42 %-1,382.22 %
201999.26 %-838.5 %-873 %
201822.62 %-1,184.06 %-1,188.2 %
201722.62 %-1,386.65 %-1,397.74 %
2016-464.2 %-849.54 %-847.07 %
2015-296.82 %-736.34 %-1,245.62 %
201426.67 %-445.83 %-592.5 %
201322.62 %0 %0 %

Nabriva Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Nabriva Therapeutics earnings per share therefore indicates how much revenue Nabriva Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nabriva Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nabriva Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nabriva Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nabriva Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nabriva Therapeutics Revenue, EBIT and net profit per share

DateNabriva Therapeutics Sales per ShareNabriva Therapeutics EBIT per shareNabriva Therapeutics Earnings per Share
2027e2.88 undefined0 undefined12.26 undefined
2026e2.51 undefined0 undefined8.31 undefined
2025e2.05 undefined0 undefined3.67 undefined
2024e1.59 undefined0 undefined-0.96 undefined
2023e1.08 undefined0 undefined-8.94 undefined
202213.77 undefined-19.08 undefined-21.32 undefined
202116.66 undefined-27.99 undefined-28.52 undefined
20209.78 undefined-128.7 undefined-135.24 undefined
20191.28 undefined-10.71 undefined-11.15 undefined
20181.9 undefined-22.52 undefined-22.59 undefined
20171.79 undefined-24.76 undefined-24.95 undefined
201630.86 undefined-262.14 undefined-261.38 undefined
201518.85 undefined-138.8 undefined-234.8 undefined
201412 undefined-53.5 undefined-71.1 undefined
20130 undefined107.25 undefined74.4 undefined

Nabriva Therapeutics business model

Nabriva Therapeutics PLC is a biopharmaceutical company based in Dublin that focuses on the research, development, and marketing of antibiotics for medical needs. The company was founded in 2006 and has since become the leading provider of antibiotics for infectious diseases in Europe and the USA. Nabriva Therapeutics' business model aims to improve the production of antibiotics for acute infections and develop innovative drugs for use in clinical practice and emergency settings. It specializes in serious and life-threatening infections such as pneumonia, bacterial skin and soft tissue infections, and bacterial infections of the urinary tract. The company is divided into two business segments: antibody therapeutics and antibiotics. Antibody therapeutics stimulate the body's immune system to better fight pathogens, while antibiotics directly combat and inhibit the growth of bacteria. Nabriva Therapeutics' flagship product is the antibiotic Xenleta (Levofloxacin) for the treatment of pneumonia. Xenleta is a bactericidal antibiotic that is effective against a variety of difficult-to-treat pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus with reduced susceptibility to Vancomycin (VSSA), acting directly on bacteria. It has been reviewed and approved by the FDA. Nabriva Therapeutics has also advanced the development of Contepo (Fosfomycin) in the field of antibiotics. Contepo is a broad-spectrum antibiotic that is effective against gram-positive and gram-negative bacteria and is intended for the treatment of infectious diseases of the urinary tract. Nabriva Therapeutics has submitted a support application to the FDA for the approval of Contepo for the therapy of complicated urinary tract infections. In August 2020, Nabriva Therapeutics announced the completion of an agreement with Taiho Pharmaceutical Co., Ltd. to market Xenleta in Brazil. The company has also entered into a collaboration with Merck and Co.'s biopharmaceutical organization to investigate the potential of Xenleta for treating patients with diseases such as bacterial skin and soft tissue infections and lung infections. Overall, Nabriva Therapeutics has played an important role in the development of antibiotics for infectious diseases and the fight against antibiotic resistance. With its innovative products and collaboration with other biopharmaceutical organizations, Nabriva Therapeutics has improved its position in the industry and strengthened its leadership in the field of antibiotic therapy. Nabriva Therapeutics is one of the most popular companies on Eulerpool.com.

Nabriva Therapeutics SWOT Analysis

Strengths

Nabriva Therapeutics is a pharmaceutical company with several competitive strengths:

  • Strong portfolio of antibiotics
  • Proven track record in developing innovative treatments
  • Robust research and development capabilities
  • Strategic partnerships with key players in the industry

Weaknesses

Although Nabriva Therapeutics has numerous strengths, it also faces certain weaknesses:

  • Relatively small market share compared to larger pharmaceutical companies
  • High dependence on successful drug development
  • Limited financial resources for extensive marketing campaigns
  • Risk of regulatory challenges and delays in drug approval

Opportunities

Nabriva Therapeutics can capitalize on the following opportunities:

  • Increasing demand for effective antibiotics
  • Growing prevalence of antibiotic-resistant infections
  • Expansion into emerging markets with unmet medical needs
  • Potential collaborations with research institutions for advancements in antibiotic research

Threats

Nabriva Therapeutics should be aware of the following threats:

  • Intense competition from established pharmaceutical companies
  • Stringent regulatory requirements and potential drug approval challenges
  • Uncertain reimbursement policies for antibiotic medications
  • Emerging alternative treatments affecting market demand

Nabriva Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Nabriva Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Nabriva Therapeutics shares outstanding

The number of shares was Nabriva Therapeutics in 2023 — This indicates how many shares 2.682 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nabriva Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nabriva Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nabriva Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nabriva Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nabriva Therapeutics stock splits

In Nabriva Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Nabriva Therapeutics.

Nabriva Therapeutics shareholders

%
Name
Stocks
Change
Date
0.27125 % Lincoln Park Capital, LLC180,50406/24/2022
0.03887 % Values First Advisors, Inc.25,868-2312/31/2022
0.03465 % Renaissance Technologies LLC23,0612,50012/31/2022
0.03350 % Susquehanna International Group, LLP22,29422,29412/31/2022
0.02558 % Frazier Healthcare Partners17,025012/31/2022
0.02104 % ACATIS Investment Kapitalverwaltungsgesellschaft GmbH14,000012/31/2022
0.01182 % Schroeder (Theodore R)7,864-4421/29/2023
0.00660 % Morgan Stanley & Co. LLC4,394012/31/2022
0.00660 % Medical Strategy GmbH4,389-18,7605/31/2022
0.00302 % Advisor Group, Inc2,008812/31/2022
1
2
3
4
5
...
8

Nabriva Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Certara Stock
Certara
SupplierCustomer0,760,880,720,870,62-
Xinjiang Tianfu Energy A Stock
Xinjiang Tianfu Energy A
SupplierCustomer0,650,780,500,700,73-0,77
BIOTON Stock
BIOTON
SupplierCustomer0,550,92-0,080,550,880,02
Roivant Sciences Stock
Roivant Sciences
SupplierCustomer0,510,640,870,640,67-
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer0,210,840,050,71-0,39-0,78
UDG Healthcare PLC Stock
UDG Healthcare PLC
SupplierCustomer0,16-0,56-0,63-0,84-0,85-
Ercros Stock
Ercros
SupplierCustomer-0,06-0,73-0,38-0,110,71-0,84
Novartis Stock
Novartis
SupplierCustomer-0,090,28-0,75-0,70-0,01-0,09
Merck & Co Stock
Merck & Co
SupplierCustomer-0,42-0,11-0,83-0,35-0,36-0,18
Sumitomo Pharma Stock
Sumitomo Pharma
SupplierCustomer-0,510,790,730,900,93-0,27
1

Most common questions regarding Nabriva Therapeutics

What values and corporate philosophy does Nabriva Therapeutics represent?

Nabriva Therapeutics PLC represents a strong commitment to advancing the field of anti-infectives and improving patient outcomes. Their corporate philosophy revolves around innovation, scientific excellence, and dedication to bringing novel treatments to market. The company is focused on addressing the global challenge of antibiotic resistance by developing and commercializing innovative antibiotics. With a patient-centric approach, Nabriva Therapeutics PLC strives to meet unmet medical needs and provide effective solutions for serious infections. Through continuous research and development efforts, they aim to contribute to the fight against infectious diseases and improve the quality of life for patients worldwide.

In which countries and regions is Nabriva Therapeutics primarily present?

Nabriva Therapeutics PLC is primarily present in the United States and Europe. The company focuses on developing innovative medications to treat serious infections. With its headquarters in Dublin, Ireland, Nabriva Therapeutics PLC has a strong presence in the European pharmaceutical market. In the United States, the company's operations center around promoting and commercializing their products to healthcare professionals and patients. Nabriva Therapeutics PLC aims to address the global need for effective antibiotics by expanding its reach and market presence.

What significant milestones has the company Nabriva Therapeutics achieved?

Nabriva Therapeutics PLC has achieved several significant milestones. Firstly, the company successfully received approval from the U.S. Food and Drug Administration (FDA) for their novel antibiotic, lefamulin, designed to treat community-acquired bacterial pneumonia (CABP). This approval marked a major milestone for Nabriva Therapeutics PLC as lefamulin became the first and only systemic oral and IV treatment approved in nearly two decades for CABP patients. Additionally, the company has made progress in expanding lefamulin's availability in Europe, receiving marketing authorization in several countries. Nabriva Therapeutics PLC's achievements demonstrate their commitment to advancing innovative solutions for infectious diseases treatment.

What is the history and background of the company Nabriva Therapeutics?

Nabriva Therapeutics PLC is a pharmaceutical company headquartered in Dublin, Ireland. Established in 2005, Nabriva focuses on developing innovative treatments to combat serious infections. The company has a strong emphasis on research and has built a robust pipeline of potential antibiotics. Nabriva Therapeutics PLC aims to address the growing global issue of antibiotic resistance through its novel approaches. With a dedicated team of experts and strategic partnerships, Nabriva Therapeutics PLC strives to improve patient outcomes and contribute to the fight against infectious diseases.

Who are the main competitors of Nabriva Therapeutics in the market?

The main competitors of Nabriva Therapeutics PLC in the market include biopharmaceutical companies such as Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, and AstraZeneca plc. These companies are also actively involved in the development and commercialization of innovative therapeutics and solutions for various medical conditions. Nabriva Therapeutics PLC competes with these industry leaders by leveraging its unique approach, research and development pipeline, and commercialization strategies.

In which industries is Nabriva Therapeutics primarily active?

Nabriva Therapeutics PLC is primarily active in the pharmaceutical industry.

What is the business model of Nabriva Therapeutics?

The business model of Nabriva Therapeutics PLC focuses on developing and commercializing innovative antibiotic treatments to address significant unmet medical needs. As a pharmaceutical company, Nabriva Therapeutics is dedicated to discovering, developing, and bringing to market novel antibiotics to combat serious infections caused by multi-drug resistant bacteria. By leveraging its expertise in antibiotics research and development, Nabriva Therapeutics aims to provide healthcare professionals with effective and safe treatment options for patients suffering from various bacterial infections. Through its continuous commitment to enhancing patient care, Nabriva Therapeutics strives to make a positive impact on global public health.

What is the P/E ratio of Nabriva Therapeutics 2024?

The Nabriva Therapeutics P/E ratio is -0.02.

What is the P/S ratio of Nabriva Therapeutics 2024?

The Nabriva Therapeutics P/S ratio is 0.01.

What is the AlleAktien quality score of Nabriva Therapeutics?

The AlleAktien quality score for Nabriva Therapeutics is 3/10.

What is the revenue of Nabriva Therapeutics 2024?

The expected Nabriva Therapeutics revenue is 105.91 M USD.

How high is the profit of Nabriva Therapeutics 2024?

The expected Nabriva Therapeutics profit is -63.8 M USD.

What is the business model of Nabriva Therapeutics

Nabriva Therapeutics PLC is a biopharmaceutical company specializing in the research, development, and commercialization of anti-infectives. The company's business model is based on providing innovative antibiotic products for the treatment of bacterial infections. They focus on developing and approving products specifically targeted against bacterial infectious diseases, including skin and soft tissue infections, outpatient respiratory tract infections, and nosocomial infections. Nabriva Therapeutics is committed to discovering and developing new and innovative therapies to meet the global demand for more effective antibiotics. The company has become a leading player in antibiotic development by conducting comprehensive drug research and development to address treatment gaps. Their three main products are Mavenclad, CONTEPO, and Lefamulin. Mavenclad is an oral Cladribine preparation for the treatment of relapsing multiple sclerosis (MS), representing a significant milestone in MS patient treatment. CONTEPO is an intravenous antibiotic for the treatment of complicated urinary tract infections, including pyelonephritis. It is the first antibiotic approved for treating infections caused by ESBL-producing Enterobacteriaceae, a growing global problem of antibiotic resistance. Lefamulin is an oral and intravenous antibiotic for the treatment of community-acquired bacterial pneumonia (CABP). It is the first antibiotic approved for CABP in the last 20 years. Nabriva Therapeutics operates a strong and extensive research and development program based on clinical studies to demonstrate the effectiveness and safety of their products. Additionally, they have a dynamic marketing program that collaborates closely with healthcare providers, clinicians, and patients to increase the availability and access to their products. The company distributes and markets its products in collaboration with a global list of partners, including a strategic partnership with Merck Sharp & Dohme Corp. (MSD) to drive the global introduction of Lefamulin. Overall, Nabriva Therapeutics has built a strong market position in the global anti-infective industry and has an excellent reputation in the field. They are positioned as a leader in the development and commercialization of antibacterial therapeutics, and with their strong research and development department and innovative products, they are on track to continue delivering successful antibiotic products to meet global demand.

What is the Nabriva Therapeutics dividend?

Nabriva Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Nabriva Therapeutics pay dividends?

The dividend cannot currently be calculated for Nabriva Therapeutics or the company does not pay out a dividend.

What is the Nabriva Therapeutics ISIN?

The ISIN of Nabriva Therapeutics is IE00BL53QQ85.

What is the Nabriva Therapeutics WKN?

The WKN of Nabriva Therapeutics is A2QKWR.

What is the Nabriva Therapeutics ticker?

The ticker of Nabriva Therapeutics is NBRV.

How much dividend does Nabriva Therapeutics pay?

Over the past 12 months, Nabriva Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nabriva Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Nabriva Therapeutics?

The current dividend yield of Nabriva Therapeutics is .

When does Nabriva Therapeutics pay dividends?

Nabriva Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nabriva Therapeutics?

Nabriva Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Nabriva Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nabriva Therapeutics located?

Nabriva Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nabriva Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nabriva Therapeutics from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Nabriva Therapeutics pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Nabriva Therapeutics in the year 2023?

In the year 2023, Nabriva Therapeutics distributed 0 USD as dividends.

In which currency does Nabriva Therapeutics pay out the dividend?

The dividends of Nabriva Therapeutics are distributed in USD.

All fundamentals about Nabriva Therapeutics

Our stock analysis for Nabriva Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nabriva Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.